Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

This was a multicenter, single-arm, open label trial, with iptacopan treatment for 24 weeks in adult PNH patients. This study was comprised of two periods: * A Screening period lasting up to 8 weeks. * A 24-week open-label, iptacopan Treatment period. After completion of the treatment period, participants who continued to benefit from the iptacopan treatment based on the study doctor's evaluation were able to join the Roll-over extension study (CLNP023C12001B).